OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 20,280 Cr.
- Current Price ₹ 1,770
- High / Low ₹ 2,250 / 1,163
- Stock P/E 147
- Book Value ₹ 516
- Dividend Yield 0.00 %
- ROCE 5.52 %
- ROE 3.34 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.46 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -17.7% over last 3 years.
- Promoters have pledged or encumbered 26.0% of their holding.
- Debtor days have increased from 86.2 to 105 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | 1,522 | |
| 93 | 132 | 199 | 254 | 978 | 1,002 | |
| Operating Profit | -71 | -4 | -161 | -82 | 467 | 519 |
| OPM % | -334% | -3% | -415% | -48% | 32% | 34% |
| 1 | -128 | -526 | -143 | -94 | -86 | |
| Interest | 16 | 46 | 48 | 89 | 166 | 141 |
| Depreciation | 34 | 53 | 66 | 76 | 274 | 275 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | 18 |
| Tax % | 0% | -0% | 0% | 0% | -73% | |
| -121 | -231 | -800 | -391 | -18 | 40 | |
| EPS in Rs | -1.57 | 3.49 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 124% |
| TTM: | 101% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| TTM: | 202% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -18% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,893 |
| 386 | 1,182 | 864 | 571 | 772 | 1,295 | |
| 96 | 248 | 365 | 459 | 1,005 | 814 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
| 633 | 1,231 | 1,361 | 863 | 6,118 | 6,286 | |
| CWIP | 431 | 490 | 334 | 188 | 218 | 173 |
| Investments | 0 | 0 | 4 | 20 | 16 | 20 |
| 195 | 722 | 314 | 356 | 1,305 | 1,535 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | |
| -207 | -692 | -68 | 511 | -201 | |
| 381 | 1,162 | 118 | -391 | 412 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 |
| Inventory Days | 87 | 615 | 258 | 222 | |
| Days Payable | 762 | 420 | 163 | 147 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 180 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -58 |
| ROCE % | -3% | -12% | -12% | 6% |
Documents
Announcements
-
Intimation Of The Press Release Of Credit Rating Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
31 Dec - India Ratings affirmed IND A-/Positive on additional bank loan facilities, rating unchanged from June 3, 2025.
- Closure of Trading Window 24 Dec
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 23 Dec
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 19 Dec
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
11 Dec - In reference to our intimation dated 09.12.2025, where the number of shares allotted was intimated as 11,45,62,136 instead of 23,000 equity shares of Re. 1/- …
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.